



**MARYLAND ADVISORY  
BOARD ON PRESCRIPTION  
DRUG MONITORING  
(PDMP)**

**February 27, 2018**

**4:00PM to 6:00 PM**

**BEHAVIORAL HEALTH  
ADMINISTRATION  
VOCATIONAL  
REHABILITATION  
BUILDING**

**55 WADE AVENUE  
CATONSVILLE, MD 21228**



**Attendees**

**Advisory Board**

Audrey Clark, MPA  
Daniel M. Ashby, MS, FASHP  
Amit Bhargava, MD, MS, RMSK  
Thomas Bond III  
Richard DeBenedetto, PharmD,  
MS, AAHIVP  
Lenna Israbin-Jamgochian,  
PharmD, RPh  
Arthur Jee, DMD (phone)  
Chris Jillson, MD  
Marcus Jones, Commander

Stephen A. Nichols, MD, FAAP,  
FAAMR  
Bonnie Oettinger, RN, MGA  
Mark Olszyk, MD, MBA, CPE,  
FACEP, FACHE, FFSMB  
Orlee Panitch, MD (phone)  
Derek Peck, Captain  
Larry Polsky, MD, MPH  
Joseph Scalese III, RPh  
Amar Setty, MD  
David Sharp, PhD (phone)

**Advisory Board Not Present**

Zachery Chattler, DPM  
Diana Shorter, DNP  
Michael Vaughn

**CRISP Representation**

Lindsey Ferris, MPH  
Rhonda Moody

**Board Adjunct:** Linda Bethman, JD, MA, Office of the Attorney General, DHMH

**MDH Staff**

Tryphena Barnes  
Kate Jackson, MPH  
Katherine Johnson  
Casey Lyons, MPH

Kathleen Rebbert-Franklin, LCSW  
Mary Viggiani, LCSW-C, LCADC  
Deb Wright

**Public**

Diana Seybolt, PhD  
Kurt Hasbert  
Leslie Grant, DDS, MSPA (phone)

## Minutes

### I. Roll Call and Introductions

The PDMP Advisory Board meeting opened with roll call and introductions of all present and attendees on the conference line.

### II. Agenda Review and Approval of Minutes

Kate Jackson reviewed the agenda, any changes to the meeting minutes should be emailed to her by end of business on Friday, March 2, 2018. Three new members were added to the Board, one present today, Lenna Israbin-Jamgochian, and two others will join the next Advisory Board meeting, Diana Shorter and Michael Vaughn. Audrey Clark, who previously acted as Board Chair, has been nominated to serve as the official Board Chair.

### III. PDMP Registration and Use Mandates

Kate provided Program updates on PDMP Registration and Use Mandates.

**Registration Process Update:** By the fall of 2017, approximately 60% of pharmacists and 70% of prescribers were PDMP-registered. A huge outreach campaign increased registrants to 86% of prescribers and 91% of pharmacists. The Program communicated the increase to the Legislature. Other state PDMPs that have a registration mandate were surveyed to assess how the mandate impacted their registration rate. Vijay Murphy, PDMP Epidemiologist, researched the top 1,000 prescribers of any CDS as reported to Maryland PDMP to determine percent of registration.

**Meeting Contingencies/System Performance:** The Office of Controlled Substances (OCSA) began enforcing the PDMP-registration requirement for receiving a new or renewed license February 15, 2018. OCSA states that their online services have been up and running since December 1, 2017. The online system will not process an application if the applicant is not registered with PDMP. The system will redirect the applicant to the CRISP registration website. Confirming an applicant's PDMP-registration status has not delayed application turnaround time.

**Use Mandate Education and Outreach:** The Use Mandate goes into effect July 1, 2018. The PDMP Steering Committee will meet every two to three weeks. Letters were sent to all health occupation boards and commissions and twenty-two professional organizations in January 2018. MedChi is providing ongoing outreach by phone and email and offering Continuing Medical Education (CME) events through June 2018. A survey of providers and practice administrators will be conducted by PDMP evaluation partners. A 'Provider Use Mandate Toolkit' consisting of educational materials based on

feedback solicited through the survey will be developed and distributed in Winter/Spring 2018.

**PDMP Use Mandate Preparation:** PDMP is focusing on three specific areas for PDMP Use Mandate preparation: CRISP system readiness, educating providers about compliance, and CRISP enhancements. For System Readiness, CRISP stress/load testing was completed early Spring 2018 to inform Section 9 contingency determination. CRISP is working on integrations into hospital electronic health records for streamlined data access and has authorized third party data intermediary products for ambulatory integration. A delegation management tool and a Provider DEA Self-Audit functionality will be deployed in CRISP.

#### **IV. CRISP Enhancements**

Lindsay Ferris gave a presentation on PDMP Overdose Alerts. The alerts support clinical decision making and allow health care providers to offer timely and informed care. Coded diagnosis data from hospitals in Maryland and West Virginia is used to identify a suspected overdose event.

#### **V. Legislative Session**

Kate reviewed six bills that were introduced during the 2018 legislative session. Four of the bills are PDMP-specific and the other two are related.

**HB88/SB1083:** The Program shall review prescription monitoring data for indications of possible misuse or abuse, and if the review indicates possible misuse or abuse, the program shall report the possible misuse or abuse to the prescriber or dispenser and provide education to the prescriber or dispenser.

**HB88/SB1083 (revisions):** Unsolicited Reporting: violations of law and breaches of professional standards- The program shall review prescription monitoring data for indications of possible violation of law and possible breach of professional standards by a prescriber or dispenser, if the review indicates a possible violation of law or possible breach of professional standards by a prescriber or dispenser, the program shall notify the prescriber or dispenser of the possible violation or breach, shall provide education to the prescriber or dispenser, and may notify the appropriate law enforcement agency or Health Occupations Board of the possible violation. In determining whether its review indicates a possible violation of law or a possible breach of professional standards by a prescriber or dispenser, the program shall obtain from the Technical Advisory Committee, clinical guidance regarding indications of a possible violation or breach, and take into account the particular specialty, circumstances of the patients, and location of the prescriber or the dispenser. Obtaining clinical guidance and interpretation of prescription monitoring data

from the Technical Advisory Committee may not delay reporting of possible violation of law or a possible breach of professional standards to a law enforcement agency or a Health Occupations Board if, in the judgment of the Program, a delay could result in imminent danger to public health or public safety.

**SB1007:** New Authorized User: Attorney General- The Program shall disclose prescription monitoring data in accordance with regulations adapted by the Secretary, to the Attorney General for the purpose of law enforcement regarding the misuse or abuse of prescriptions.

**HB517:** Use Mandate Exemption for Regional Anesthesia- A prescriber is not required to request prescription monitoring data from the program if the opioid or benzodiazepine is prescribed or dispensed to an individual to treat or prevent acute pain for a period of not more than 14 days following a surgical procedure in which general anesthesia or regional anesthesia, including spinal and epidural techniques were used; specific to fractures, significant trauma, and childbirth.

**HB1716:** New Authorized User: Insurance Carrier- The Program shall disclose prescription monitoring data to a carrier, as defined in 31-101, of the Insurance article for the purpose of determining the medical necessity of a prescription drug claim.

**Other Bills:** Kate mentioned two additional bills that are not PDMP-related but on her radar: HB1416: Electronic Prescriptions and HB1452: Authorized Providers-Continuing Medical Education.

## **VI. Board Member Feedback and Discussion**

Dr. Ashby mentioned MedChi provides continuing medical education credits.

Kate provided a short PDMP Educational Video on the importance of the PDMP. The video contains detailed information on the PDMP program, why providers should register, registration instructions, and pertinent information on overdose-related fatalities. The video will be shared at conferences and available on the PDMP website.

## **VII. PDMP Annual Report Vote**

PDMP staff will circulate a draft version of the Annual Report that includes track-changes to the Advisory Board by the end of the week. All Advisory Board members should submit final edits and revisions by Thursday March 1, 2018. A final version will then be shared for review and a vote on Friday March 2, 2018. Once approved, the report will be reviewed by others in the Department of Health before going to the General Assembly.

PDMP staff requested recommendations for the Program to be included in the Annual Report. The Board recommended focusing on implementing the currently expanded legislative authorities and requirements before attempting to undertake additional legal requirements or authorities.

### **VIII. Announcement**

The next PDMP Board meeting (phone meeting) is scheduled for Thursday, April 19, 2018 at 3:00pm.

### **IX. Public Discussion**

Question: Dr. Leslie Grant asked if the September 2015 informational flyer is still appropriate to distribute to colleagues and constituents.

Answer: The flyer is being revised and a new version will be posted on the PDMP website. PDMP staff are updating the flyer with information about the PDMP registration requirement for renewal of the CDS permit and Use Mandate information.

Question: Is there a way to clear up the confusion for individuals who are not logging on to CRISP often and getting locked out of the system and having to reset their password?

Answer: Guidance is provided in the FAQ.

### **Meeting Adjourned**